LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Aandelen Lijst・Compugen Ltd

Compugen Ltd

Gesloten

2.03 -2.87

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

2.12

Belangrijke statistieken
By Trading Economics
Inkomsten	-65M -7.7M
Verkoop	-65M 2.2M
K/W Sectorgemiddelde	6.474 49.888
EPS	-0.08
Winstmarge	-352.436
Werknemers	75
EBITDA	-64M -7.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+138.1% upside

Dividenden
By Dow Jones
Volgende Winsten	5 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-38M 233M
Vorige openingsprijs	4.9
Vorige sluitingsprijs	2.03

Compugen Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jun 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Belangrijke Marktbewegers

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Marktinformatie

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Marktinformatie

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Acquisities, Fusies, Overnames

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Acquisities, Fusies, Overnames

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Marktinformatie

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Marktinformatie

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Marktinformatie

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Marktinformatie

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Marktinformatie

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Marktinformatie

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Marktinformatie

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Marktinformatie

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Acquisities, Fusies, Overnames

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Acquisities, Fusies, Overnames

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Marktinformatie

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Marktinformatie

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Marktinformatie

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Vergelijking

Prijswijziging

Compugen Ltd Prognose

Koersdoel

By TipRanks

138.1% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5 USD 138.1%

Hoogste 6 USD

Laagste 4 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Compugen Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Compugen Ltd - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.